Download PDF
Thromb Haemost 1999; 82(05): 1443-1445
DOI: 10.1055/s-0037-1614852
Rapid Communications
Schattauer GmbH

An Inhibitory Anti-factor IX Antibody Effectively Reduces Thrombus Formation in a Rat Model of Venous Thrombosis

Giora Z. Feuerstein
1   From SmithKline Beecham Pharmaceuticals, Departments of Cardiovascular Pharmacology, King of Prussia, PA, USA
,
John R. Toomey
1   From SmithKline Beecham Pharmaceuticals, Departments of Cardiovascular Pharmacology, King of Prussia, PA, USA
,
Richard Valocik
1   From SmithKline Beecham Pharmaceuticals, Departments of Cardiovascular Pharmacology, King of Prussia, PA, USA
,
Paul Koster
1   From SmithKline Beecham Pharmaceuticals, Departments of Cardiovascular Pharmacology, King of Prussia, PA, USA
,
Arun Patel
2   Protein Biochemistry and Structural Biology, King of Prussia, PA, USA
,
Michael N. Blackburn
3   Protein Biochemistry and Structural Biology, King of Prussia, PA, USA
› Author Affiliations
Further Information

Publication History

Received 21 April 1999

Accepted after revision 13 July 1999

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

An inhibitory anti-factor IX/IXa antibody (BC2) has been investigated as an anti-thrombotic agent in a rat venous thrombosis model. The treatment of rats post-injury with a single bolus dose of BC2 (3mg/kg, iv.) resulted in an ~4 fold reduction in venous thrombus mass (P = 0.043). This efficacy was matched by a minimal (<2.5 fold) prolongation of the aPTT and had no effect on the prothrombin time (PT). Heparin by comparison, given as a bolus followed by continuous infusion, at doses comparable in efficacy at reducing thrombus formation, prolonged the aPTT >50 fold. These results demonstrate that the anti-factor IX/IXa antibody (BC2), when compared to heparin, can effectively reduce venous thrombosis with less disruptive consequences on blood clotting.

Keywords

Antibodies - anticoagulants - thrombosis - factor IX
 

  • References

  • 1 Appleby RD, Olds RJ. The inherited basis of venous thrombosis. Pathology 1997; 29: 41-347.
    CrossrefPubMedGoogle Scholar
  • 2 Dunbabin DW. Prophylaxis against deep venous thrombosis and pulmonary embolism in patients with stroke. Vasc Med 1996; 1: 207-12.
    CrossrefPubMedGoogle Scholar
  • 3 Walenga JM, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clinics North Amer 1998; 82: 635-58.
    PubMedGoogle Scholar
  • 4 Holmer E, Kurachi K, Soderstrom G. The molecular weight dependence of the rate enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor Xla, factor XIIa and kallikrein by anti-thrombin. Biochem J 1981; 193: 395-400.
    CrossrefPubMedGoogle Scholar
  • 5 Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995; 77: 175-85.
    CrossrefPubMedGoogle Scholar
  • 6 Hamamoto T, Kisiel W. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1996; 7: 470-6.
    CrossrefPubMedGoogle Scholar
  • 7 Hirsh J. Low-molecular-weight heparin. Circulation 1998; 98: 1575-1582.
    CrossrefPubMedGoogle Scholar
  • 8 Mast AE. Low-molecular-weight-heparin. In: Vascular Surgery: Theory and Practice. Stamford: Appleton and Lange; Callow A, Ernst C. eds: 1995: 847-56.
    Google Scholar
  • 9 Kelley RF, Refino CJ, O’Connell MP, Modi N, Sehl P, Lowe D, Pater C, Bunting S. A soluble tissue factor mutant is a selective anti-coagulant and anti-thrombotic agent. Blood 1997; 89: 3219-27.
    PubMedGoogle Scholar
  • 10 Holst J, Kristensen AT, Kristensen HI, Ezban M, Hedner U. Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model. Eur J Vasc Endovasc Surg 1998; 15: 515-20.
    CrossrefPubMedGoogle Scholar
  • 11 Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A, Blackburn MN. Anti-thrombotic efficacy of a novel murine anti-human factor IX antibody in rats. Arterioscler Thromb Vasc Biol. 1999 In press.
    PubMedGoogle Scholar
  • 12 Schumacher WA, Heran CL. Effect of thromboxane receptor antagonists on venous thrombosis in rats. J Pharmacol Exp Therap 1989; 248: 1109-15.
    PubMedGoogle Scholar
  • 13 Tollefsen DM, Blinder MA. Heparin. In: Hematology – Basic Principles and Practice. Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE. eds: New York: Churchill Livingstone; 1995: 1802-13.
    Google Scholar
  • 14 Lecompte T, Luo SK, Stieltjes N, Lecrubier C, Samama MM. Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991; 338: 1217.
    PubMedGoogle Scholar
  • 15 Lollar P, Fass DN. Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-anginyl-chloromethylketone. Arch Biochem Biophys 1984; 233: 438-46.
    CrossrefPubMedGoogle Scholar
  • 16 Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, Stern D. Active site blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991; 88: 1760-5.
    CrossrefPubMedGoogle Scholar
  • 17 Spanier TB, Oz MC, Madigan JD, Rose EA, Stern DM, Nowygrod R, Schmidt AM. Selective anti-coagulation with active site blocked factor IXa in synthetic patch vascular repair results in decreased blood loss and operative time. ASAIO 1997; 43: M526-M530.
    CrossrefPubMedGoogle Scholar
  • 18 Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 1995; 86: 1794-1801.
    PubMedGoogle Scholar
  • 19 Mann KG, Kalafatis M. The coagulation explosion. Cerebrovasc Dis 1995; 5: 93-7.
    CrossrefPubMedGoogle Scholar